Clinical Trial of Tolcapone for Cognition in Schizophrenia
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well
as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention
Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the
frontal cortex of the brain.
...